FDA timeline pushes mifepristone fight past midterms into 2027

The Food and Drug Administration told a federal court that its safety review of mifepristone will continue into 2027, making major federal action on abortion-pill prescribing, mailing or dispensing rules unlikely before this year’s midterm elections. The timeline sets up a post-election fight over regulation and litigation.¹

In a late Oct. 7 filing in federal court in Louisiana, the agency said it expects to obtain study results by mid-December 2026 and complete a report on the findings by March 2027.¹ Reuters also reported that the FDA said the review would be completed by March, a timeline that could become the basis for later restrictions on telehealth prescribing or mail dispensing.²

The filing is the first substantive court update on a review ordered under Health Secretary Robert F. Kennedy Jr. and closely watched by abortion opponents, abortion-rights groups, states and drug-regulation lawyers.

Mifepristone, approved by the FDA in 2000, is used with misoprostol in the most common medication-abortion regimen in the United States. The agency has repeatedly reaffirmed its safety and effectiveness while easing some access rules over time.¹

Court schedule slows immediate policy action

The new timeline means the administration is not positioned to impose immediate nationwide restrictions before the November elections. The Hill reported that the FDA’s five-page update said the agency would not publish the safety review until March and would not impose new restrictions before then.³ Stateline reported that the schedule aligns with a broader delay in controversial abortion policy decisions until after the midterms.⁴

The update came in Louisiana v. FDA, a lawsuit challenging federal rules that allow mifepristone to be prescribed through telehealth and mailed to patients. Louisiana argues those policies undermine its abortion ban. Similar litigation is pending or has been filed by other states, including Missouri and Texas.³⁴

AP reported that a 5th U.S. Circuit Court of Appeals panel recently questioned parts of Louisiana’s case, including whether the state has standing to challenge FDA oversight of the drug.¹

Even if the appeals court acts, AP reported that the legal landscape would not immediately change because the Supreme Court has blocked changes to mifepristone access until it reviews the case again.¹ That leaves the FDA’s administrative review, rather than an immediate court order, as the likely next vehicle for any change in national policy.

Anti-abortion groups push for faster restrictions

Anti-abortion organizations and congressional allies have pressed the Trump administration to revisit mifepristone access, especially rules adopted during and after the COVID-19 pandemic that allowed remote prescribing and mail delivery.¹ OSV News reported that anti-abortion groups called the FDA timeline insufficient and urged the administration not to wait until the review is complete before acting.⁵

National Review reported conservative movement frustration with the delay, including criticism that the agency had not yet reinstated in-person dispensing requirements.⁶ Baptist Press reported that telehealth prescribing remains in place while the review continues, drawing objections from abortion opponents who want the administration to curtail virtual prescribing and mailing of the drug sooner.⁷

The pressure campaign has focused on the FDA’s Risk Evaluation and Mitigation Strategy, or REMS, for mifepristone. The Hill reported that the agency told the court it is separately reviewing that safety program and must examine hundreds of citations in citizen petitions seeking changes to prescribing and distribution rules, including a possible return to in-person dispensing.³

Stateline reported that anti-abortion groups have promoted research using commercially available Medicaid claims data to argue that complications are undercounted. Medical and abortion-rights groups dispute those claims and continue to describe mifepristone as safe and effective.⁴ OSV News reported that Reproductive Freedom for All called the review a political effort and argued that the administration was delaying action because restrictions would be unpopular with voters.⁵

What FDA could do next

If the FDA concludes that changes are warranted, the next steps would be administrative rather than automatic. The agency said it would decide after the study and review whether changes to the Mifepristone REMS Program are necessary and, if so, initiate them through established processes.³⁶

Those steps could include responding to pending citizen petitions, revising REMS requirements, changing prescribing or dispensing conditions, and addressing whether mifepristone may continue to be prescribed through telehealth and delivered by mail. Reuters framed the review as a possible basis for limiting telehealth prescribing and mail dispensing, two access points at the center of the current court fights.²

Any such move would likely generate new litigation. States seeking tighter restrictions could argue the FDA did not go far enough. Abortion-rights groups, providers, drugmakers or states supporting access could challenge new limits as unsupported by evidence or procedurally flawed.

Talking Points Memo reported that the filing signals a post-midterm regulatory path for the administration, with the Louisiana case serving as a key forum for the dispute.⁸

For now, the Biden-era rules remain in place. The practical effect of the Oct. 7 filing is to defer the most consequential federal decisions on mifepristone until after the elections, while preserving a court-monitored process that could reshape medication-abortion access in 2027.